Skip to main content Skip to footer
American Family Children's Hospital
Natalie S. Callander, MD close
Natalie S. Callander, MD

New Patients

Need help selecting a primary care doctor? Contact the Welcome Center for personal assistance.

For Referring Physicians

How to refer a patient

Natalie S. Callander, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Callander joined the section of Hematology/Bone Marrow Transplant at the University of Wisconsin in October 2004 as an Associate Professor in the Department of Medicine. Dr. Callander has completed residency at Bellevue Hospital in New York and a Hematology/Oncology fellowship at the University of California-San Diego.



UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map
UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map

Hospital Affiliation(s)

University Hospital
Veterans Hospital - Wm. S. Middleton Memorial

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Hematology
Internal Medicine
Medical Oncology
Fellowship University of California San Diego Medical Center, San Diego, CA
Residency Bellevue Hospital, New York, NY
Internship Bellevue Hospital, New York, NY
Medical School Tufts University School of Medicine, Boston, MA

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.

Her clinical and research interests include: inpatient and outpatient care of hematology and bone marrow transplant patients and multiple myeloma.

PubMed Articles
Huynh M Pak C Markovina S Callander NS Chng KS Wuerzberger-Davis SM Bakshi DD Kink JA Hematti P Hope C Asimakopoulos F Rui L Miyamoto S Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma. J Biol Chem . 2018 Feb 16;293(7):2452-2465
[PubMed ID: 29279332]
Turcotte LM Wang T Hemmer MT Spellman SR Arora M Couriel D Alousi A Pidala J Abdel-Azim H Ahmed I Beitinjaneh A Buchbinder D Byrne M Callander N Chao N Choi SW DeFilipp Z Gadalla SM Gale RP Gergis U Hashmi S Hematti P Holmberg L Inamoto Y Kamble RT Lehmann L MacMillan MA McIver Z Nishihori T Norkin M O'Brien T Olsson RF Reshef R Saad A Savani BN Schouten HC Seo S Solh M Verdonck L Vij R Wirk B Yared J Horowitz MM Knight JM Verneris MR Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. Bone Marrow Transplant . 2018 Jan 30;
[PubMed ID: 29382954]
Chang JE Carmichael LL Kim K Peterson C Yang DT Traynor AM Werndli JE Huie MS McFarland TA Volk M Blank J Callander NS Longo WL Kahl BS VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study. Clin Lymphoma Myeloma Leuk . 2018 Jan;18(1):e61-e67
[PubMed ID: 29191715]
Jared JR Mably MS Makielski R Reed MP Fallon MJ Liu G Mulkerin D Callander NS Utilization and evaluation of noncore chemotherapy regimens within an academic medical center. J Oncol Pharm Pract . 2017 Oct;23(7):518-524
[PubMed ID: 27388159]
Hope C Emmerich PB Papadas A Pagenkopf A Matkowskyj KA Van De Hey DR Payne SN Clipson L Callander NS Hematti P Miyamoto S Johnson MG Deming DA Asimakopoulos F Versican-Derived Matrikines Regulate Batf3-Dendritic Cell Differentiation and Promote T Cell Infiltration in Colorectal Cancer. J Immunol . 2017 Sep 1;199(5):1933-1941
[PubMed ID: 28754680]
Holstein SA Jung SH Richardson PG Hofmeister CC Hurd DD Hassoun H Giralt S Stadtmauer EA Weisdorf DJ Vij R Moreb JS Callander NS van Besien K Gentile TG Isola L Maziarz RT Bashey A Landau H Martin T Qazilbash MH Rodriguez C McClune B Schlossman RL Smith SE Hars V Owzar K Jiang C Boyd M Schultz C Wilson M Hari P Pasquini MC Horowitz MM Shea TC Devine SM Linker C Anderson KC McCarthy PL Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol . 2017 Sep;4(9):e431-e442
[PubMed ID: 28826616]
Hope C Foulcer S Jagodinsky J Chen SX Jensen JL Patel S Leith C Maroulakou I Callander N Miyamoto S Hematti P Apte SS Asimakopoulos F Immunoregulatory roles of versican proteolysis in the myeloma microenvironment. Blood . 2016 Aug 4;128(5):680-5
[PubMed ID: 27259980]
Lonial S Weiss BM Usmani SZ Singhal S Chari A Bahlis NJ Belch A Krishnan A Vescio RA Mateos MV Mazumder A Orlowski RZ Sutherland HJ Bladé J Scott EC Oriol A Berdeja J Gharibo M Stevens DA LeBlanc R Sebag M Callander N Jakubowiak A White D de la Rubia J Richardson PG Lisby S Feng H Uhlar CM Khan I Ahmadi T Voorhees PM Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet . 2016 Apr 9;387(10027):1551-60
[PubMed ID: 26778538]
Jurczyszyn A Olszewska-Szopa M Vesole AS Vesole DH Siegel DS Richardson PG Paba-Prada C Callander NS Huras H Skotnicki AB Multiple Myeloma in Pregnancy--A Review of the Literature and a Case Series. Clin Lymphoma Myeloma Leuk . 2016 Mar;16(3):e39-45
[PubMed ID: 26847816]
Hari P Aljitawi OS Arce-Lara C Nath R Callander N Bhat G Allen LF Stockerl-Goldstein K A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation. Biol Blood Marrow Transplant . 2015 Dec;21(12):2100-2105
[PubMed ID: 26327631]
D'Souza A Dispenzieri A Wirk B Zhang MJ Huang J Gertz MA Kyle RA Kumar S Comenzo RL Peter Gale R Lazarus HM Savani BN Cornell RF Weiss BM Vogl DT Freytes CO Scott EC Landau HJ Moreb JS Costa LJ Ramanathan M Callander NS Kamble RT Olsson RF Ganguly S Nishihori T Kindwall-Keller TL Wood WA Mark TM Hari P Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. J Clin Oncol . 2015 Nov 10;33(32):3741-9
[PubMed ID: 26371138]
Scheid C Reece D Beksac M Spencer A Callander N Sonneveld P Kalimi G Cai C Shi M Scott JW Stewart AK Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation. Eur J Haematol . 2015 Oct;95(4):316-24
[PubMed ID: 25402977]
Stewart AK Jacobus S Fonseca R Weiss M Callander NS Chanan-Khan AA Rajkumar SV Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. Blood . 2015 Sep 10;126(11):1294-301
[PubMed ID: 26157076]
Jensen JL Rakhmilevich A Heninger E Broman AT Hope C Phan F Miyamoto S Maroulakou I Callander N Hematti P Chesi M Bergsagel PL Sondel P Asimakopoulos F Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma. Cancer Immunol Res . 2015 Aug;3(8):881-90
[PubMed ID: 25941352]
Shah N Callander N Ganguly S Gul Z Hamadani M Costa L Sengsayadeth S Abidi M Hari P Mohty M Chen YB Koreth J Landau H Lazarus H Leather H Majhail N Nath R Osman K Perales MA Schriber J Shaughnessy P Vesole D Vij R Wingard J Giralt S Savani BN American Society for Blood and Marrow Transplantation. Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant . 2015 Jul;21(7):1155-66
[PubMed ID: 25769794]
Gupta A Place M Goldstein S Sarkar D Zhou S Potamousis K Kim J Flanagan C Li Y Newton MA Callander NS Hematti P Bresnick EH Ma J Asimakopoulos F Schwartz DC Single-molecule analysis reveals widespread structural variation in multiple myeloma. Proc Natl Acad Sci U S A . 2015 Jun 23;112(25):7689-94
[PubMed ID: 26056298]
Pak C Callander NS Young EW Titz B Kim K Saha S Chng K Asimakopoulos F Beebe DJ Miyamoto S MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells. Integr Biol (Camb) . 2015 Jun;7(6):643-54
[PubMed ID: 25998180]
Kumar SK LaPlant B Chng WJ Zonder J Callander N Fonseca R Fruth B Roy V Erlichman C Stewart AK Mayo Phase 2 Consortium. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood . 2015 Jan 15;125(3):443-8
[PubMed ID: 25395429]
Sharma M Zhang MJ Zhong X Abidi MH Akpek G Bacher U Callander NS Dispenzieri A Freytes CO Fung HC Gale RP Gasparetto C Gibson J Holmberg LA Kindwall-Keller TL Klumpp TR Krishnan AY Landau HJ Lazarus HM Lonial S Maiolino A Marks DI Mehta P Mikhael Med JR Nishihori T Olsson R Ramanathan M Roy V Savani BN Schouten HC Scott E Tay J To LB Vesole DH Vogl DT Hari P Older patients with myeloma derive similar benefit from autologous transplantation. Biol Blood Marrow Transplant . 2014 Nov;20(11):1796-803
[PubMed ID: 25046833]
Callander N Markovina S Eickhoff J Hutson P Campbell T Hematti P Go R Hegeman R Longo W Williams E Asimakopoulos F Miyamoto S Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network. Cancer Chemother Pharmacol . 2014 Oct;74(4):875-82
[PubMed ID: 25168296]